The office of Mallinckrodt’s regional Asia/Pacific headquarters in Singapore has been awarded “business headquarters” status by the Singapore Economic Development Board.Mallinckrodt’s business tax rate will be reduced to 13% from
The office of Mallinckrodts regional Asia/Pacific headquarters in Singapore has been awarded business headquarters status by the Singapore Economic Development Board.
Mallinckrodts business tax rate will be reduced to 13% from 25% for the five years of the status, said Robert Martsching, Mallinckrodt investor spokesman. The business development designation was awarded in recognition of the pharmaceutical and medical imaging companys commitment to regional business growth.
Singapore business development officials say they hope to establish Mallinckrodt as one of the most dynamic and fastest growing healthcare companies in the Asia/Pacific region. Mallinckrodts regional headquarters in Singapore has 34 employees and is headed by Kin Chua, president of Mallinckrodt Asia/Pacific.
Staff members provide marketing, technical, financial, and administrative support to Mallinckrodt offices and employees throughout the Pacific Rim, including Australia, China, Hong Kong, India, Korea, Japan, and Taiwan. Mallinckrodts Singapore office has established a clinical education center to enhance the technical skills of providers, distributors, and employees.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.